Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-hydroxymilbemycin Beta7
2. Cl 301,423
3. Cl 301423
4. Cydectin
5. Milbeknock
6. Milbemectin
7. Milbemycin A3
8. Milbemycin A4
9. Milbemycin Alpha1
10. Milbemycin Alpha10
11. Milbemycin Alpha11
12. Milbemycin Alpha13
13. Milbemycin Alpha14
14. Milbemycin Alpha15
15. Milbemycin Alpha2
16. Milbemycin Alpha3
17. Milbemycin Alpha4
18. Milbemycin Alpha5
19. Milbemycin Alpha6
20. Milbemycin Alpha7
21. Milbemycin Alpha8
22. Milbemycin Alpha9
23. Milbemycin B
24. Milbemycin Beta1
25. Milbemycin Beta12
26. Milbemycin Beta2
27. Milbemycin Beta3
28. Milbemycin D
29. Milbemycins
30. Mixture Of Milbemycins A3 And A4
1. 113507-06-5
2. Proheart 6
3. Ngu5h31yo9
4. Cl 301,423
5. Nsc-760424
6. (1r,4s,4'e,5's,6r,6's,8r,10e,13r,14e,16e,20r,21r,24s)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(e)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
7. Cl-301,423
8. (6r,25s)-5-o-demethyl-28-deoxy-25-((e)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-oxomilbemycin B 23-(e)-(o-methyloxime)
9. Milbemycin B
10. Moxidectina
11. Moxidectine
12. Moxidectinum
13. Moxidectine [inn-french]
14. Moxidectinum [inn-latin]
15. Unii-ngu5h31yo9
16. Moxidectina [inn-spanish]
17. Moxidectin [usan:inn:ban]
18. Moxidectin (tn)
19. (2ae,2'r,4e,4'e,5's,6r,6's,8e,11r,15s,17ar,20r,20ar,20bs)-6'-[(1e)-1,3-dimethylbut-1-enyl]-20,20b-dihydroxy-4'-(methoxyimino)-5',6,8,19-tetramethyl-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradeca
20. Hydrospiro[2h,17h-11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-17-one
21. Moxidectin [mi]
22. Moxidectin (usp/inn)
23. Moxidectin [inn]
24. Moxidectin [usan]
25. Moxidectin [mart.]
26. Moxidectin [usp-rs]
27. Moxidectin [who-dd]
28. Moxidectin For Veterinary Use
29. Moxidectin [green Book]
30. Chembl2104415
31. Dtxsid5037577
32. Moxidectin [orange Book]
33. Schembl13112872
34. Chebi:183811
35. Moxidectin [usp Monograph]
36. Advocate Component Moxidectin
37. Hy-b0777
38. Mfcd00866560
39. S3713
40. Akos025401990
41. Zinc253476173
42. Ccg-270317
43. Db11431
44. Moxidectin Component Of Advocate
45. Nsc 760424
46. Moxidectin [ema Epar Veterinary]
47. (2ae,4e,5'r,6r,6's,8e,11r,13s,15s,17ar,20r,20ar,20bs)-6'-((e)-1,3-dimethyl-1-butenyl)-5',6,6',7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5',6,8,19-tetramethylspiro(11,15-methano-2h,13h,17h-furo(4,3,2-pq)(2,6)benzodioxacyclooctadecin-13,2'-(2h)pyran)-4',17(3'h)-dione 4'-(e)-(o-methyloxime)
48. Ac-27773
49. As-17881
50. Moxidectin 100 Microg/ml In Acetonitrile
51. Cl-301423
52. M3136
53. D05084
54. Moxidectin, Vetranal(tm), Analytical Standard
55. 507m065
56. Moxidectin For Veterinary Use [ep Monograph]
57. Moxidectin, European Pharmacopoeia (ep) Reference Standard
58. Moxidectin, United States Pharmacopeia (usp) Reference Standard
59. Moxidectin, Pharmaceutical Secondary Standard; Certified Reference Material
60. Moxidectin For System Suitability, European Pharmacopoeia (ep) Reference Standard
61. Milbemycin B, 5-o-demethyl-28-deoxy-25-((1e)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6r,23e,25s)-
62. Milbemycin B, 5-o-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6r,23e,25s(e))-
63. Milbemycin B, 5-o-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-,(6r,23e,25s(e))-
Molecular Weight | 639.8 g/mol |
---|---|
Molecular Formula | C37H53NO8 |
XLogP3 | 4.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 639.37711765 g/mol |
Monoisotopic Mass | 639.37711765 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 1340 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 10 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 5 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Moxidectin is indicated for the treatment of river blindness, also called onchocerciasis, in patients aged 12 years and older. River blindness is caused by a parasitic worm _Onchocerca volvulus_ and it is manifested as severe itching, disfiguring skin conditions and visual impairment caused by the worm's larvae. The transmission of _Onchocerca volvulus_ is performed person to person by black flies that breed in fast-flowing rivers in sub-Saharan Africa, Yemen and South and Central America. The larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestations.
FDA Label
Moxidectin has been reported to be highly effective against _Onchocerca volvulus_ when compared to ivermectin. When moxidectin was administered in infected individuals, the microfilarial load in the skin was lower even when compared to the current therapy, ivermectin. The levels of microfilarial got reduced to an undetectable level while being safe to be used in mass drug administration.
Anthelmintics
Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)
Antinematodal Agents
Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)
Insecticides
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)
P - Antiparasitic products, insecticides and repellents
P02 - Anthelmintics
P02C - Antinematodal agents
P02CX - Other antinematodals
P02CX03 - Moxidectin
Absorption
The penetration of moxidectin in the parasite is not restricted as this compound is a very poor substrate of p-glycoprotein, which is vital for the reduction of the uptake of lipophilic compounds from the GI tract and for the increase in biliary, intestinal and renal secretion. After oral administration of moxidectin, the plasma maximal concentration of 70.4 mg/kg was reached after 0.37 day with a reported AUC of 363.6 mcg/day/ml. It is also important to mention that oral bioavailability is enhanced with the co-administration with lipids.
Route of Elimination
When moxidectin is orally administered, 2% of the dose is eliminated unchanged in the feces within 72 hours. Renal elimination is negligible.
Volume of Distribution
Moxidectin presents a larger volume of distribution and mean residence time when compared to ivermectin. The reported volume of distribution is of 1.2 l/kg.
Clearance
The apparent clearance of moxidectin is 3.5 L/hour.
Reports have registered enzymatic modification in humans and in nematodes. In the case of moxidectin, there has been registered C29-30- and C14-mono-hydroxymethyl derivatives mainly by the cytochrome CYP3A and CYP2B. The metabolism of moxidectin is considered to contribute to a small extent to the elimination. Some other metabolites formed are O-demethyl-dihydroxy metabolites. The metabolism of the of moxidectin is not major as the major residue in fat, liver, kidney and muscle is the unchanged moxidectin.
Moxidectin reporter terminal half-life is 20.2 days.
Moxidectin selectively binds to the parasite's GABA-A and glutamate-gated chloride ion channels which are vital for the function of invertebrate nerve and muscle cells. It presents activity against the parasite but it does not kill him. Once moxidectin is bound, there is an increased permeability leading to an influx of chloride ions and flaccid paralysis of the parasite.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29420
Submission : 2015-05-19
Status : Active
Type : II
Certificate Number : R1-CEP 2017-134 - Rev 00
Issue Date : 2023-01-26
Type : Chemical
Substance Number : 1656
Status : Valid
NDC Package Code : 20076-1245
Start Marketing Date : 2015-01-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35909
Submission : 2021-05-30
Status : Active
Type : II
Certificate Number : CEP 2021-423 - Rev 01
Issue Date : 2024-04-22
Type : Chemical
Substance Number : 1656
Status : Valid
NDC Package Code : 42513-0018
Start Marketing Date : 2021-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6097
Submission : 2015-01-22
Status : Active
Type : II
Certificate Number : R1-CEP 2008-103 - Rev 00
Issue Date : 2014-12-03
Type : Chemical
Substance Number : 1656
Status : Valid
Certificate Number : R1-CEP 2012-384 - Rev 02
Issue Date : 2021-12-13
Type : Chemical
Substance Number : 1656
Status : Valid
Certificate Number : CEP 2017-188 - Rev 02
Issue Date : 2024-08-20
Type : Chemical
Substance Number : 1656
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35909
Submission : 2021-05-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29420
Submission : 2015-05-19
Status : Active
Type : II
VMF Number : 6084
Submission : 2014-09-12
Status : Active
Type : II
VMF Number : 6031
Submission : 2012-12-04
Status : Active
Type : II
VMF Number : 6172
Submission : 2016-11-02
Status : Active
Type : II
VMF Number : 6097
Submission : 2015-01-22
Status : Active
Type : II
VMF Number : 6425
Submission : 2021-04-29
Status : Active
Type : II
VMF Number : 5446
Submission : 1993-01-27
Status : Inactive
Type : II
VMF Number : 5451
Submission : 1993-03-12
Status : Inactive
Type : II
VMF Number : 5519
Submission : 1994-09-26
Status : Active
Type : II
VMF Number : 5528
Submission : 1994-12-08
Status : Inactive
Type : II
VMF Number : 5445
Submission : 1993-01-27
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Reply
04 Dec 2024
Reply
24 Oct 2024
Reply
26 Mar 2024
Reply
27 Nov 2021
Reply
16 Sep 2020
Reply
05 Dec 2019
Reply
22 Nov 2019
Reply
08 Aug 2019
Reply
18 Jun 2019
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Moxidectin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Moxidectin, including repackagers and relabelers. The FDA regulates Moxidectin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Moxidectin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Moxidectin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Moxidectin supplier is an individual or a company that provides Moxidectin active pharmaceutical ingredient (API) or Moxidectin finished formulations upon request. The Moxidectin suppliers may include Moxidectin API manufacturers, exporters, distributors and traders.
click here to find a list of Moxidectin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Moxidectin DMF (Drug Master File) is a document detailing the whole manufacturing process of Moxidectin active pharmaceutical ingredient (API) in detail. Different forms of Moxidectin DMFs exist exist since differing nations have different regulations, such as Moxidectin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Moxidectin DMF submitted to regulatory agencies in the US is known as a USDMF. Moxidectin USDMF includes data on Moxidectin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Moxidectin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Moxidectin suppliers with USDMF on PharmaCompass.
A Moxidectin CEP of the European Pharmacopoeia monograph is often referred to as a Moxidectin Certificate of Suitability (COS). The purpose of a Moxidectin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Moxidectin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Moxidectin to their clients by showing that a Moxidectin CEP has been issued for it. The manufacturer submits a Moxidectin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Moxidectin CEP holder for the record. Additionally, the data presented in the Moxidectin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Moxidectin DMF.
A Moxidectin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Moxidectin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Moxidectin suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Moxidectin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Moxidectin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Moxidectin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Moxidectin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Moxidectin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Moxidectin suppliers with NDC on PharmaCompass.
Moxidectin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Moxidectin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Moxidectin GMP manufacturer or Moxidectin GMP API supplier for your needs.
A Moxidectin CoA (Certificate of Analysis) is a formal document that attests to Moxidectin's compliance with Moxidectin specifications and serves as a tool for batch-level quality control.
Moxidectin CoA mostly includes findings from lab analyses of a specific batch. For each Moxidectin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Moxidectin may be tested according to a variety of international standards, such as European Pharmacopoeia (Moxidectin EP), Moxidectin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Moxidectin USP).
LOOKING FOR A SUPPLIER?